Research programme: potassium channel agonists - Valeant Pharmaceuticals

Drug Profile

Research programme: potassium channel agonists - Valeant Pharmaceuticals

Alternative Names: VRX 698

Latest Information Update: 26 Mar 2012

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Carbamates; Phenylenediamines; Small molecules
  • Mechanism of Action KCNQ potassium channel agonists; Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Epilepsy; Neurological disorders

Most Recent Events

  • 29 Feb 2012 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
  • 29 Feb 2012 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
  • 29 Aug 2008 Valeant Pharmaceuticals International and GlaxoSmithKline agree to co-promote and co-develop potassium channel agonists worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top